Overview On Surgical Management Of Overactive Bladder
Main Article Content
Abstract
Overactive bladder syndrome is a persistent and incapacitating disorder that has profound medical, psychological, and social implications, greatly impacting the wellbeing of countless individuals globally. A significant number of individuals experience urine urgency, which can be extremely bothersome. The primary indicator of overactive bladder (OAB) is a sense of urgency, often accompanied by increased urine frequency and nocturia. After ruling out other medical conditions with similar symptoms, the initial approach to managing OAB is providing guidance on fluid consumption and bladder training. If needed, antimuscarinic medicines may be added as a supplement. If patients have significant distress from OAB symptoms even after maximizing medicinal treatment, they may choose to undergo invasive procedures. There is currently a limited understanding of the hierarchical structure of central nervous system control. However, the use of functional imaging is starting to reveal the difficulties that need to be addressed in this area. Current research is exploring the use of botulinum neurotoxin-A injection, oral β3-adrenergic agonists, and innovative methods for nerve stimulation as potential therapies. The inherent subjectivity of urine urgency, the absence of animal models, and the complex pathophysiology of overactive bladder (OAB) pose substantial obstacles to achieving effective clinical therapy.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Wein AJ, Rackley RR. Overactive bladder: A better understanding of pathophysiology, diagnosis and management. J Urol. 2006;175:S5–10.
Tyagi S, Thomas CA, Hayashi Y, Chancellor MB. The overactive bladder: Epidemiology and morbidity. Urol Clin North Am. 2006;33:433–8.
Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P.
International Continence Society: Reviewing the ICS 2002 terminology report: The ongoing debate. Neurourol Urodyn. 2009;28:287.
Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive Bladder Syndrome: Evaluation and Management. Curr Urol. 2018;11(3):117-125. doi:10.1159/000447205
Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study [published correction appears in BJU Int 2001 Nov;88(7):807]. BJU Int. 2001;87(9):760-766. doi:10.1046/j.1464-410x.2001.02228.x
Coyne KS, Sexton CC, Kopp ZS, Ebel-Bitoun C, Milsom I, Chapple C. The impact of overactive bladder on mental health, work productivity and healthrelated quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011;108(9):1459-1471. doi:10.1111/j.1464-410X.2010.10013.x
Donaldson MM, Thompson JR, Matthews RJ, Dallosso HM, McGrother CW; Leicestershire MRC Incontinence Study Group. The natural history of overactive bladder and stress urinary incontinence in older women in the community: a 3-year prospective cohort study. Neurourol Urodyn.2006;25(7):709-716. doi:10.1002/nau.20235
Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–36.
McGrother CW, Donaldson MM, Hayward T, Matthews R, Dallosso HM, Hyde C. Leicestershire MRC Incontinence Study Team. Urinary storage symptoms and comorbidities: A prospective population cohort study in middle-aged and older women. Age Ageing. 2006;35:16–24.
Teleman PM, Lidfeldt J, Nerbrand C, Samsioe G, Mattiasson A. WHILA study group. O7men. BJOG. 2004;111:600–4.
Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy. 2005;25:511–9.
Hu TW, Wagner TH. Health-related consequences of overactive bladder: An economic perspective. BJU Int. 2005;96:43–5.
Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ. 2003;326(7394):841-844. doi:10.1136/bmj.326.7394.841
Robinson D, Cardozo L. Managing overactive bladder. Climacteric, 2019;22(3), 250-256.
Fontaine C, Papworth E, Pascoe J, Hashim H. Update on the management of overactive bladder. Therapeutic Advances in Urology. 2021;13. doi:10.1177/17562872211039034
Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306-1315. doi:10.1016/j.eururo.2006.09.019
Irwin DE, Milsom I, Kopp Z, Abrams P, Artibani W, Herschorn S. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol. 2009;56(1):14-20. doi:10.1016/j.eururo.2009.02.026
Lee YS, Lee KS, Jung JH, et al. Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study. World J Urol. 2011;29(2):185-190. doi:10.1007/s00345-009-0490-1 19- Dallosso, H. M., Matthews, R. J., McGrother, C. W., Donaldson, M. M. & Shaw, C. The association of diet and other lifestyle factors with the onset of overactive bladder: a longitudinal study in men. Public Health Nutr. 7, 885– 891 (2004).
Gulur D, Drake M. Management of overactive bladder. Nat Rev Urol 2010;7, 572–582. https://doi.org/10.1038/nrurol.2010.147.
American Urological Association. Overactive Bladder (OAB) guideline,
https://www.auanet.org/guidelines/overactive-bladder-(oab)guideline (2020, accessed 29 December 2020).
Truzzi JC, Gomes CM, Bezerra CA, et al. Overactive bladder – 18 years – Part I. Int Braz J Urol 2016; 42: 188–198.
European Association of Urology. EAU Guidelines: urinary incontinence,
https://uroweb.org/guideline/urinary-incontinence/ (2020, accessed 29 December 2020).
Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity?. J Urol 2006; 175: 191–194.
Markland AD, Vaughan CP, Johnson TM II, et al. Incontinence. Med Clin North Am 2011; 95: 539–554.
Wells MJ, Jamieson K, Markham TC, et al. The effect of caffeinated versus decaffeinated drinks on overactive bladder: a double-blind, randomized, crossover study. J Wound Ostomy Continence Nurs 2014; 41: 371–378.
Pelletier EM, Vats V, Clemens JQ. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder. Am J Manag Care 2009; 15(Suppl. 4): S108–S114.
Willis-Gray MG, Dieter AA, Geller EJ. Evaluation and management of overactive bladder: strategies for optimizing care. Res Rep Urol. 2016;8:113- 122. Published 2016 Jul 27. doi:10.2147/RRU.S93636
Burkhard FC, Bosch JLHR, Cruz F, Lemack GE, Nambiar AK, Thiruchelvam N,
Tubaro A, Ambühl D, Bedretdinova DA, Farag F, et al: Urinary Incontinence in Adults. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam, 2020. https://uroweb.org/guideline/urinary-incontinence/. Access date: March 21, 2021.
Scarneciu I, Lupu S, Bratu OG, Teodorescu A, Maxim LS, Brinza A, ... Scarneciu CC. Overactive bladder: A review and update. Experimental and Therapeutic Medicine, 2021;22, 1444. https://doi.org/10.3892/etm.2021.10879
Vasdev N, Biles BD, Sandher R, Hasan TS. The surgical management of the refractory overactive bladder. Indian J Urol. 2010;26(2):263-269. doi:10.4103/0970-1591.65402
Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008; 180: 217–222.
Sahai A, Khan MS, Dasgupta P; GKT Botulinum Study Group. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007; 177: 2231–2236.
Amundsen CL, Komesu YM, Chermansky C, et al. Two-year outcomes of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: a randomized trial. Eur Urol 2018; 74: 66–73.
Ghoniem G. Use of new rechargeable battery and MRI-Friendly technologies in sacral neuromodulation systems to treat fecal incontinence. Japanese J Gstro Hepato 2020; 5: 1–5.
de Wall LL, Heesakkers JP. Effectiveness of percutaneous tibial nerve stimulation in the treatment of overactive bladder syndrome. Res Rep Urol 2017; 9: 145–157.
Peters KM, Carrico DJ, Wooldridge LS, et al. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol 2013; 189: 2194–2201.
Biardeau X, Chartier-Kastler E, Rouprêt M, et al. Risk of malignancy after augmentation cystoplasty: a systematic review. Neurourol Urodyn 2016; 35: 675–682.
Noblett KL, Dmochowski RR, Vasavada SP, et al. Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome. Neurourol Urodyn 2017; 36: 727–733.